-
公开(公告)号：US11267897B2
公开(公告)日：2022-03-08
申请号：US16173114
申请日：2018-10-29
Applicant: INNATE PHARMA
Inventor： Laurent Gauthier , Nadia Anceriz , Ariane Morel , Benjamin Rossi
Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
-
公开(公告)号：US20200024357A1
公开(公告)日：2020-01-23
申请号：US16443744
申请日：2019-06-17
Applicant: Innate Pharma
Inventor： Stéphanie Chanteux , Laurent Gauthier , Nicolas Gourdin , Carine Paturel , Ivan Perrot , Benjamin Rossi
IPC: C07K16/28 , A61P35/00 , G01N33/574
Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
-
公开(公告)号：US11891444B2
公开(公告)日：2024-02-06
申请号：US17315547
申请日：2021-05-10
Applicant: INNATE PHARMA
Inventor： Laurent Gauthier , Nadia Anceriz , Ariane Morel , Benjamin Rossi
CPC classification number: C07K16/2803 , C07K16/2809 , C07K16/2887 , C07K16/468 , C12N5/10 , C12N15/00 , C12N15/64 , C12N15/66 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/526 , C07K2317/622 , C07K2317/732 , C07K2317/92 , C12N2511/00 , C12N2523/00
Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
-
公开(公告)号：US11377503B2
公开(公告)日：2022-07-05
申请号：US16443744
申请日：2019-06-17
Applicant: Innate Pharma
Inventor： Stéphanie Chanteux , Laurent Gauthier , Nicolas Gourdin , Carine Paturel , Ivan Perrot , Benjamin Rossi
IPC: C07K16/28 , A61P35/00 , G01N33/574
Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
-
公开(公告)号：US11208480B2
公开(公告)日：2021-12-28
申请号：US15321674
申请日：2015-06-23
Applicant: INNATE PHARMA
Inventor： Laurent Gauthier , Benjamin Rossi
Abstract: Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.
-
Patent Agency Ranking
公开(公告)号：US12252543B2
公开(公告)日：2025-03-18
申请号：US16173150
申请日：2018-10-29
Applicant: INNATE PHARMA
Inventor： Laurent Gauthier , Nadia Anceriz , Ariane Morel , Benjamin Rossi
IPC: C07H21/00 , A61K39/00 , C07K16/28 , C12N15/86 , C12N5/0783
Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
-
公开(公告)号：US12202907B2
公开(公告)日：2025-01-21
申请号：US17855510
申请日：2022-06-30
Applicant: Innate Pharma , Orega Biotech
Inventor： Stéphanie Chanteux , Laurent Gauthier , Nicolas Gourdin , Carine Paturel , Ivan Perrot , Benjamin Rossi
IPC: C07K16/28 , A61P35/00 , G01N33/574
Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
-
8.发明授权公开(公告)号：US11447545B2
公开(公告)日：2022-09-20
申请号：US16629585
申请日：2018-07-09
Applicant: INNATE PHARMA
Inventor： Stéphanie Cornen , Benjamin Rossi , Nicolai Wagtmann
Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
-
公开(公告)号：US11078274B2
公开(公告)日：2021-08-03
申请号：US16082959
申请日：2017-03-07
Applicant: INNATE PHARMA
Inventor： Stephanie Cornen , Benjamin Rossi , Nicolai Wagtmann
IPC: C07K16/28 , A61K47/68 , A61P35/00 , C12N5/12 , G01N33/574
Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
-
公开(公告)号：US20190218308A1
公开(公告)日：2019-07-18
申请号：US16370726
申请日：2019-03-29
Applicant: INNATE PHARMA
Inventor： Stéphanie Chanteux , Nicolas Gourdin , Carine Paturel , Ivan Perrot , Benjamin Rossi
IPC: C07K16/40 , A61P35/00 , G01N33/574 , C07K16/28 , A61K9/00
CPC classification number: C07K16/2896 , A61K39/001154 , A61K2039/507 , A61K2039/545 , A61P35/00 , C07K2317/565 , C07K2317/74 , C07K2317/92 , C12N9/14
Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.018 seconds)
